Black Rock Inc. Surrozen, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.44 - $0.89 $454,243 - $918,811	1,032,372 Added 2851.94%	1,068,571 $523,000
Q2 2023 Aug 11, 2023	SELL	$0.55 - $0.72 $27,627 - $36,166	-50,231 Reduced 58.12%	36,199 $19,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.32 $900 - $2,122	1,608 Added 1.9%	86,430 $51,000
Q4 2022 Feb 13, 2023	BUY	$0.42 - $41.25 $81 - $8,002	194 Added 0.23%	84,822 $49,000
Q3 2022 Nov 14, 2022	SELL	$0.26 - $46.35 $3,770 - $672,075	-14,500 Reduced 14.63%	84,628 $171,000
Q2 2022 Aug 12, 2022	BUY	$2.14 - $3.43 $134,668 - $215,846	62,929 Added 173.84%	99,128 $298,000
Q4 2021 Feb 10, 2022	BUY	$6.0 - $9.92 $7,440 - $12,300	1,240 Added 3.55%	36,199 $233,000
Q3 2021 Nov 09, 2021	BUY	$6.98 - $12.03 $244,013 - $420,556	34,959 New	34,959 $248,000

4.52M

Ticker SRZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,122,900
Market Cap $327M
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, a...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.